Today the results of the @PlussTrial were published in @JAMA_current!
Intratracheal budesonide mixed with surfactant to increase survival free of BPD in extremely preterm infants born <28 weeks’ gestation
https://t.co/hRD0SpQDLV
A thread 🧵 (1/X) #neotwitter
Huge congratulations to the @PlussTrial team and our amazing statisticians, Kate Francis and Susan Donath, for their double win at the @ACTA_org Trial of the Year Awards! 🎉The ACTA STInG Excellence in Statistics Award recognizes their commitment to rigorous trial methodologies.
Today the @PlussTrial was awarded the @ACTA_org Clinical Trial of the Year!!!
As always the first people to thank are the incredible families and babies of who took part in the trial 🙏🏻
And of course thanks and congratulations to the entire @PlussTrial team!
#neoTwitter
The most recent @AAPneonatal Journal Club webinar is available - https://t.co/UZ1ZhjHbIj
Dr. Aung (Neonatal-Perinatal Fellow, St. Christopher's Hospital) gave an excellent overview of the PLUSS trial. Thank you to @drbretty and Dr. Watterberg for joining! #neotwitter@NeoTECaN
Today the results of the @PlussTrial were published in @JAMA_current!
Intratracheal budesonide mixed with surfactant to increase survival free of BPD in extremely preterm infants born <28 weeks’ gestation
https://t.co/hRD0SpQDLV
A thread 🧵 (1/X) #neotwitter
In extremely preterm infants receiving surfactant, early intratracheal budesonide may have little to no effect on survival free of bronchopulmonary dysplasia. @PlussTrial
https://t.co/ltHT2bb78n
Did your baby participate? Published today in @JAMA_current - the results of The @PlussTrial!
21 NICUs in 4 countries - Australia, New Zealand, Canada & Singapore - enrolled just over 1060 babies.
@drbretty joins us!
WATCH THE FULL EPISODE --> https://t.co/uIerQzhUaX
Thanks go first and foremost to the amazing babies and their families that participated in the @plusstrial! 🙏🏻
And to the sponsor @MCRI_for_kids and funders incl. @nhmrc and @ChiesiGroup
And of course to the wonderful group of investigators who made it all happen!
(13/END)
We powered the @PlussTrial to find a 10% increase in the primary outcome of survival free of BPD at 36w PMA: from 50% to 60%
We needed 1038 infants and we aimed for 1060
The trial recruited in 21 tertiary NICUs in 4 countries (mainly 🇦🇺 & 🇳🇿, 1 centre in 🇸🇬 and 1 in 🇨🇦)
(6/X)
So, disappointingly 😔, the @PlussTrial found that intratracheal budesonide mixed with surfactant had little or no effect on survival free of BPD in EPTIs…
Longer term outcomes are important and we are currently assessing participants at 2 years of age (PLUSS2)
(12/X)